CytoMed Therapeutics Launches Innovative CAR-T Cell Therapy Trial
CytoMed Therapeutics Limited (NASDAQ: GDTC), a prominent biopharmaceutical company based in Singapore, has received the green light for its groundbreaking Phase I clinical trial, known as the ANGELICA Trial. This trial explores the efficacy of a patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) therapy aimed at treating both blood and solid tumors. With significant financial backing from the National Medical Research Council (NMRC) through the Clinical Trial Grant, CytoMed is set to transform the landscape of cancer treatment.
Understanding CAR-T Cell Therapy
CAR-T cell therapy has emerged as a dynamic approach to oncology. This personalized therapy modifies a patient's own T cells by attaching a synthetic protein to target cancer cells specifically. The modified cells are reintroduced into the patient's body where they seek out and destroy malignancies without harming healthy cells, differentiating them from traditional chemotherapy that indiscriminately targets all rapidly dividing cells.
Benefits of the ANGELICA Trial
The ANGELICA Trial utilizes blood derived from healthy young donors, which is expected to lead to a higher quality of manufactured CAR-T cells. This approach not only lowers production costs but also facilitates quicker patient access to treatment, thanks to its potential for bulk production.
Unique Immune Cell Application
One of the distinctive features of CytoMed's trial is the use of gamma delta T cells instead of the conventional alpha-beta T cells. Gamma delta T cells can be sourced from healthy donors and do not require matching, making them versatile for various patients combating advanced cancer.
Expert Insights on the Trial
Dr. Anand Jeyasekharan, who leads this pioneering trial, emphasizes its unique approach to allogeneic CAR-T cell therapy, particularly for solid tumors. His team of experts has meticulously crafted the trial protocol to maximize its effectiveness and safety, ensuring that patients with relapsed cancers have access to innovative treatment options.
Dr. Tan Wee Kiat, Co-CEO and COO of CytoMed, expressed optimism about the trial and its potential contributions to the advancement of blood-derived immunotherapy in Singapore and globally.
Two-Part Trial Approach
The ANGELICA Trial consists of two segments. Currently, Part 1 is focused on recruiting healthy blood donors at the National University Hospital (NUH). Following this, Part 2 will aim to recruit patients suffering from advanced cancers that are unresponsive to standard therapies. This systematic approach could represent a significant milestone in patient care.
Acquisition of Cord Blood Bank
In an exciting development, CytoMed has also acquired assets of a licensed cord blood bank in Malaysia, enhancing its portfolio in cell-based therapies. This acquisition opens up new avenues utilizing cord blood-derived biologics, which bear potential for regenerative medicine and treatment of aging-related conditions, thus augmenting CytoMed's innovative capabilities.
Future Conferences and Opportunities
On October 8, CytoMed will hold an earnings call discussing its recent financials. This meeting represents an opportunity for stakeholders to engage with the management team and inquire about the company's future directions and the ANGELICA Trial outcomes.
Engagement with Investors
The management team will also be in New York City for meetings with shareholders from late October, allowing investors keen on CytoMed's path forward to discuss matters in person.
About CytoMed Therapeutics Limited
Founded in 2018 as a spin-off from Singapore’s A*STAR, CytoMed is dedicated to advancing the field of cancer treatment through innovative biopharmaceutical technologies. With a focus on developing novel, cell-based allogeneic therapies using proprietary gamma delta T cell technology, CytoMed aims to offer new hope to patients suffering from various malignancies.
Frequently Asked Questions
What is the ANGELICA Trial?
The ANGELICA Trial is a Phase I clinical study focusing on using CAR-T cell therapy for treating blood and solid tumors.
What types of cells are used in CytoMed's trial?
The trial utilizes gamma delta T cells, sourced from healthy donors, allowing for a versatile application without the need for donor matching.
Who is leading the ANGELICA Trial?
Dr. Anand Jeyasekharan, a Senior Consultant at the National University Cancer Institute in Singapore, serves as the lead investigator.
What support has CytoMed received for this trial?
The trial has received co-funding from the National Medical Research Council under its Clinical Trial Grant scheme.
How does this trial differ from traditional CAR-T therapies?
This trial seeks to provide off-the-shelf CAR-T therapy using donor-derived gamma delta T cells, which operate with lower matching requirements and aim for quicker patient access.
